THE US Food and Drug
Administration has granted
approval to Inflectra (inflimax-dyyb)
for a range of indications.
Inflectra is a biosimilar to Janssen
Biotech’s Remicade (infliximab)
which was first licensed in 1988.
Under the new FDA approval
Inflectra can be prescribed for
the treatment of Crohn’s disease,
ulcerative colitis, rheumatoid
arthritis, ankylosing spondylitis,
psioratic arthritis and chronic
severe plaque psoriasis.The above article was sent to subscribers in Pharmacy Daily's issue from 07 Apr 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Apr 16
DEMENTIA Australia has appointed comedian Geraldine Hickey (pictured) as its newest Ambassador, coinciding with the Melbourne Memory Walk & Jog event taking place this Sun.
NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia’s most populous states.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.